$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024044731 Filed on May 17, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$117.1K	$1.205K	$128.3K
YoY Change	1817.53%	-99.06%	399.89%
Cost Of Revenue	$190.00	$277.00	$60.24K
YoY Change	-99.74%	-99.54%	3070.32%
Gross Profit	$117.0K	$928.00	$68.04K
YoY Change	-274.89%	-98.64%	186.35%
Gross Profit Margin	99.84%	77.01%	53.04%
Selling, General & Admin	$640.5K	$831.3K	$1.273M
YoY Change	-53.82%	-34.69%	-78.37%
% of Gross Profit	547.62%	89575.11%	1870.7%
Research & Development	$40.40K	$69.07K	$335.0K
YoY Change	-92.15%	-79.38%	-6.79%
% of Gross Profit	34.54%	7442.46%	492.36%
Depreciation & Amortization	$13.31K	$1.286K	$6.493K
YoY Change	90.15%	-80.19%	20.02%
% of Gross Profit	11.38%	138.58%	9.54%
Operating Expenses	$1.094M	$3.445M	$1.974M
YoY Change	-48.58%	74.52%	-68.37%
Operating Profit	-$976.6K	-$3.444M	-$1.906M
YoY Change	-55.48%	80.7%	-69.35%
Interest Expense	-$429.6K	$684.7K	$56.66K
YoY Change	-474.38%	1108.34%	91.88%
% of Operating Profit
Other Income/Expense, Net	-$406.9K	-$536.6K	$8.954K
YoY Change	925.35%	-6093.18%	-39.13%
Pretax Income	-$1.384M	-$3.981M	-$1.897M
YoY Change	-38.05%	109.83%	-69.27%
Income Tax	-$110.9K
% Of Pretax Income
Net Earnings	-$1.273M	-$3.933M	-$1.824M
YoY Change	-43.77%	115.66%	-70.04%
Net Earnings / Revenue	-1086.45%	-326388.05%	-1421.74%
Basic Earnings Per Share	-$0.09	-$0.40	-$0.06
Diluted Earnings Per Share	-$0.09	-$0.40	-$0.06
COMMON SHARES
Basic Shares Outstanding	10.85M shares	10.56M shares	33.08M shares
Diluted Shares Outstanding	11.32M shares	9.736M shares	33.08M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$200.0K	$106.4K	$1.213M
YoY Change	13.57%	-91.23%	-56.89%
Cash & Equivalents	$124.3K	$30.49K	$1.135M
Short-Term Investments	$75.68K	$75.92K	$78.01K
Other Short-Term Assets	$719.3K	$788.1K	$1.005M
YoY Change	-9.06%	-21.56%	-50.01%
Inventory
Prepaid Expenses
Receivables	$1.530K	$1.530K	$124.1K
Other Receivables	$1.258M	$887.9K	$520.0K
Total Short-Term Assets	$2.190M	$1.794M	$3.480M
YoY Change	2.85%	-48.44%	-56.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.929M	$7.949M	$571.6K
YoY Change	1305.02%	1290.74%	-71.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.378M	$2.475M	$849.8K
YoY Change	185.86%	191.17%	-6.02%
Other Assets	$1.409M	$1.411M	$3.489M
YoY Change	-59.86%	-59.56%	192.38%
Total Long-Term Assets	$12.44M	$12.67M	$7.255M
YoY Change	73.04%	74.59%	77.87%
TOTAL ASSETS
Total Short-Term Assets	$2.190M	$1.794M	$3.480M
Total Long-Term Assets	$12.44M	$12.67M	$7.255M
Total Assets	$14.63M	$14.46M	$10.73M
YoY Change	57.01%	34.7%	-11.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$3.680M	$3.513M	$2.763M
YoY Change	6.92%	27.13%	73.08%
Deferred Revenue	$79.50K	$79.50K
YoY Change
Short-Term Debt	$847.0K	$860.8K	$902.0K
YoY Change	-4.05%	-4.57%	-43.97%
Long-Term Debt Due	$956.9K	$842.6K
YoY Change
Total Short-Term Liabilities	$6.549M	$6.634M	$5.075M
YoY Change	13.44%	30.71%	38.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$3.207M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$256.5K	$339.8K	$718.9K
YoY Change	-58.28%	-52.73%	-30.98%
Total Long-Term Liabilities	$256.5K	$339.8K	$3.926M
YoY Change	-93.45%	-91.34%	276.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.549M	$6.634M	$5.075M
Total Long-Term Liabilities	$256.5K	$339.8K	$3.926M
Total Liabilities	$6.805M	$6.973M	$9.000M
YoY Change	-29.75%	-22.52%	93.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.37M	-$69.35M	-$56.73M
YoY Change	19.28%	22.26%
Common Stock	$12.05K	$10.70K	$33.08K
YoY Change	264.33%	-67.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.902M	$8.902M	$9.100M
YoY Change	-2.17%	-2.17%
Treasury Stock Shares
Shareholders Equity	$8.293M	$7.792M	$1.670M
YoY Change
Total Liabilities & Shareholders Equity	$14.63M	$14.46M	$10.73M
YoY Change	57.01%	34.7%	-11.04%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$1.273M	-$3.933M	-$1.824M
YoY Change	-43.77%	115.66%	-70.04%
Depreciation, Depletion And Amortization	$13.31K	$1.286K	$6.493K
YoY Change	90.15%	-80.19%	20.02%
Cash From Operating Activities	-$1.014M	-$473.2K	-$1.498M
YoY Change	12.7%	-68.41%	-49.98%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$1.000M
YoY Change
Cash From Financing Activities	868.5K	$676.2K	$2.207M
YoY Change	-2849.41%	-69.36%
NET CHANGE
Cash From Operating Activities	-1.014M	-$473.2K	-$1.498M
Cash From Investing Activities
Cash From Financing Activities	868.5K	$676.2K	$2.207M
Net Change In Cash	-145.6K	-$57.78K	$400.2K
YoY Change	-89.39%	-114.44%	-112.96%
FREE CASH FLOW
Cash From Operating Activities	-$1.014M	-$473.2K	-$1.498M
Capital Expenditures			$0.00
Free Cash Flow			-$1.498M
YoY Change			-48.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3307577	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9736150	shares
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
CY2024Q1	dei	Entity Address Country EntityAddressCountry	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
CY2024Q1	dei	City Area Code CityAreaCode	(510)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	668-0881
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10851823	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30489	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60155	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	628513	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	656625	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1530	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1530	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	75916	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	79312	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	159602	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	101051	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1794450	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1656709	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7949150	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7969278	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	708023	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	809283	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	2474514	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	2527740	usd
CY2024Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	75416	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	78789	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	60644	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	62442	usd
CY2024Q1	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	1274842	usd
CY2023Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	1274842	usd
CY2024Q1	us-gaap	Assets Assets	14460402	usd
CY2023Q4	us-gaap	Assets Assets	14492599	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	860750	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	899250	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4050845	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3696380	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	79500	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	79500	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	108110	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	112946	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	389870	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	401826	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	842567	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	569456	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6633614	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5932490	usd
CY2024Q1	us-gaap	Security Deposit Liability SecurityDepositLiability	21680	usd
CY2023Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	21680	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	318153	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	407457	usd
CY2024Q1	us-gaap	Liabilities Liabilities	6973447	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6361627	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10698315	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10698315	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7940298	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7940298	shares
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86029237	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82636966	usd
CY2024Q1	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	225740	usd
CY2023Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	451480	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69353071	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65420095	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	233323	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	516387	usd
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	8902371	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	8901668	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7792076	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8388050	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	-305121	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-257078	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7486955	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8130972	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14460402	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14492599	usd
CY2024Q1	us-gaap	Revenues Revenues	1205	usd
CY2023Q1	us-gaap	Revenues Revenues	128272	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	277	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	60236	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	928	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	68036	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	831257	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1272752	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69066	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	334979	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2544995	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	366489	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3445318	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1974220	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3444390	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1906184	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	4049	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	52711	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	684683	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	56663	usd
CY2023Q1	us-gaap	Interest Paid InterestPaid	22100	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	113520	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-12261	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30485	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3067	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-536629	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8954	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3981019	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1897230	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3981019	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1897230	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-48043	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-73535	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3932976	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1823695	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-283064	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	29109	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4216040	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1794586	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9736150	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3307577	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3981019	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1897230	usd
CY2024Q1	us-gaap	Depreciation Depreciation	1286	usd
CY2023Q1	us-gaap	Depreciation Depreciation	6493	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2544995	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	366489	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-672016	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1521	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-113339	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	53380	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	203621	usd
CY2024Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	140364	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	110720	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	354465	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-146316	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	128840	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	375454	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-473161	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1497633	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	394071	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	282095	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3206587	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	676166	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2206587	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-260783	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-308804	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57778	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	400150	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	716780	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1391728	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	659002	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1791878	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	5701	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	56663	usd
CY2024Q1	abvc	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	-681000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	140749	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	225740	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1897230	usd
CY2023Q1	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	29109	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1734507	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8130972	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	383500	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	681000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	394071	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2161495	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3981019	usd
CY2024Q1	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	-283064	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7486955	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3981019	usd
CY2024Q1	abvc	Working Capital Deficit WorkingCapitalDeficit	4839164	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-473161	usd
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications of Prior Year Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year unaudited consolidated interim balance sheet and unaudited consolidated cash flow statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2023, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock. The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase the per share trading value of the Company’s common stock, although that outcome is not guaranteed. In turn, the Company believes that the Reverse Stock Split will enable the Company to restore compliance with certain continued listing standards of NASDAQ Capital Market. All shares and related financial information in this Form 10-Q reflect this 1-for-10 reverse stock split. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30489	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60155	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	628513	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	656625	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company performs ongoing credit evaluation of our customers and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1	srt	Financing Receivable Before Allowance For Credit Loss To Total Percent FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent	0.8724	pure
CY2023Q4	srt	Financing Receivable Before Allowance For Credit Loss To Total Percent FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent	0.8724	pure
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.8478	pure
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	616448	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	616505	usd
CY2024Q1	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2023Q1	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2024Q1	abvc	Labor Pension Fund Per Month LaborPensionFundPerMonth	0.06	pure
CY2024Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2024Q1	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	2379	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	2804	usd
CY2024Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1935755	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2024Q1	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	609240	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	366489	usd
CY2024Q1	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
CY2024Q1	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
CY2015	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	50000000	twd
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1640000	usd
CY2018Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	50
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.64
CY2018Q4	abvc	Equity Method Long Term Investment EquityMethodLongTermInvestment	1530000	shares
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	549	usd
CY2022Q2	abvc	Service Agreement Eligibility Amount ServiceAgreementEligibilityAmount	3000000	usd
CY2022Q2	abvc	Milestone Regulatory Payment Amount Period MilestoneRegulatoryPaymentAmountPeriod	P3Y
CY2024Q1	us-gaap	Loans Payable LoansPayable	1000000	usd
CY2024Q1	abvc	Working Capital Convertible Loan Percentage WorkingCapitalConvertibleLoanPercentage	0.05	pure
CY2024Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	1
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11271552	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11304319	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3322402	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3335041	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7949150	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7969278	usd
CY2024Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	37000000	usd
CY2024Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	7400000	usd
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	370000	shares
CY2024Q1	us-gaap	Share Price SharePrice	20
CY2024Q1	us-gaap	Depreciation Depreciation	1286	usd
CY2023Q1	us-gaap	Depreciation Depreciation	6493	usd
CY2024Q1	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<span style="font-size: 10pt">The ownership percentages of each investee are listed as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name of related party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Genepharm Biotech Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.67</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.67</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.68</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.68</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26.65</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26.65</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	810977	usd
CY2023Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	847252	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	2474514	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	2527740	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2688578	usd
CY2022	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	1895556	usd
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	994450	shares
CY2024Q1	abvc	Percentage Common Stocks Shares PercentageCommonStocksShares	0.2665	pure
CY2023	abvc	Percentage Common Stocks Shares PercentageCommonStocksShares	0.2665	pure
CY2023Q1	us-gaap	Shares Issued SharesIssued	5291667	shares
CY2024Q1	abvc	Outstanding Principal Amount OutstandingPrincipalAmount	308650.58	usd
CY2024Q1	abvc	Percentage Of Cash Permium PercentageOfCashPermium	0.05	pure
CY2023Q3	abvc	Percentage Of Outstanding Principal Amount PercentageOfOutstandingPrincipalAmount	1.15	pure
CY2024Q1	us-gaap	General Partners Capital Account GeneralPartnersCapitalAccount	12500000	usd
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3.5
CY2023Q4	us-gaap	Receivable With Imputed Interest Face Amount ReceivableWithImputedInterestFaceAmount	1200000	usd
CY2023Q4	abvc	Purchase Warrant Term PurchaseWarrantTerm	P5Y
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	480795	usd
CY2024Q1	abvc	Conversion Price Per Share ConversionPricePerShare	1
CY2024Q1	us-gaap	Receivable With Imputed Interest Face Amount ReceivableWithImputedInterestFaceAmount	1000000	usd
CY2024Q1	abvc	Purchase Price Amount PurchasePriceAmount	833333	usd
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	3.5
CY2024Q1	abvc	Percentage Of Average Amount PercentageOfAverageAmount	0.90	pure
CY2024Q1	abvc	Purchase Warrant Term PurchaseWarrantTerm	P5Y
CY2024Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1000000	usd
CY2024Q1	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	2
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	394071	usd
CY2024Q1	abvc	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1799583	usd
CY2023Q4	abvc	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1799583	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1061083	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1184505	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	262296	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	274028	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	927883	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	438264	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4050845	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3696380	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	860750	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	899250	usd
CY2020Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	350000	usd
CY2020Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	350000	usd
CY2021Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	650000	usd
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1000000	usd
CY2024Q1	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	1736	usd
CY2023Q1	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	10209	usd
CY2024Q1	us-gaap	Other Receivable Allowance For Credit Loss Noncurrent OtherReceivableAllowanceForCreditLossNoncurrent	839983	usd
CY2023Q4	us-gaap	Other Receivable Allowance For Credit Loss Noncurrent OtherReceivableAllowanceForCreditLossNoncurrent	839983	usd
CY2024Q1	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	123363	usd
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	113516	usd
CY2022Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.05	pure
CY2022Q2	abvc	Working Capital Percentage WorkingCapitalPercentage	0.064	pure
CY2024Q1	abvc	Description Of Conversion Price DescriptionOfConversionPrice	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
CY2024Q1	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	500000	usd
CY2023Q4	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	500000	usd
CY2024Q1	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	38819	usd
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	38819	usd
CY2024Q1	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	123363	usd
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	113516	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	346565	usd
CY2024Q1	abvc	Outstanding Principal And Accrued Interests OutstandingPrincipalAndAccruedInterests	145858	usd
CY2023Q4	abvc	Outstanding Principal And Accrued Interests OutstandingPrincipalAndAccruedInterests	152382	usd
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	5938	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	4896	usd
CY2024Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	644978	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	713223	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5607804	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5568391	usd
CY2024Q1	abvc	Operating Lease Liabilities OperatingLeaseLiabilities	213482	usd
CY2023Q4	abvc	Operating Lease Liabilities OperatingLeaseLiabilities	213482	usd
CY2024Q1	abvc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	-213482	usd
CY2023Q4	abvc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	-213482	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6252782	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6281614	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6252782	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6281614	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	3704167	usd
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	1.05
CY2023Q3	us-gaap	Investment Sold Not Yet Purchased Balance Shares InvestmentSoldNotYetPurchasedBalanceShares	751795	shares
CY2023Q3	us-gaap	Investment Sold Not Yet Purchased Balance Principal Amount InvestmentSoldNotYetPurchasedBalancePrincipalAmount	681000	usd
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	300000	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.5
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1200000	usd
CY2023Q4	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	1000000	usd
CY2023Q4	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	3.5
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.90	pure
CY2023Q4	us-gaap	Credit Derivative Term1 CreditDerivativeTerm1	P5Y
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	480795	usd
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	1
CY2024Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1000000	usd
CY2024Q1	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	833333	usd
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	3.5
CY2024Q1	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.90	pure
CY2024Q1	us-gaap	Credit Derivative Term1 CreditDerivativeTerm1	P5Y
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000000	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	545182	shares
CY2020Q4	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	2
CY2020Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	abvc	Number Of Directors NumberOfDirectors	11	pure
CY2021Q4	abvc	Number Of Employees NumberOfEmployees	3	pure
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	abvc	Number Of Directors NumberOfDirectors	5	pure
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2587104	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.79
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M26D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2587104	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.79
CY2024Q1	abvc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Ending Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2	P7Y8M26D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2587104	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M26D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2587104	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.79
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M26D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0279	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8386	pure
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	708023	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	809283	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	389870	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	401826	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	318153	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	407457	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	98502	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	94299	usd
CY2024Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	98502	usd
CY2023Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	94299	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M23D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0146	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.015	pure
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	303008	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	350809	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	56916	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	710733	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2711	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	708022	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Interest Paid InterestPaid		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023Q1	abvc	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt		usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2024Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent		usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	abvc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grant Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm
CY2024Q1	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	abvc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
CY2024Q1	abvc	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001173313

Files In Submission

Name	View Source	Status
abvc-20240331_lab.xml	Edgar Link	unprocessable
0001213900-24-044731-index-headers.html	Edgar Link	pending
0001213900-24-044731-index.html	Edgar Link	pending
0001213900-24-044731.txt	Edgar Link	pending
0001213900-24-044731-xbrl.zip	Edgar Link	pending
abvc-20240331.xsd	Edgar Link	pending
ea0205718-10q_abvcbio.htm	Edgar Link	pending
ea020571801ex31-1_abvcbio.htm	Edgar Link	pending
ea020571801ex31-2_abvcbio.htm	Edgar Link	pending
ea020571801ex32-1_abvcbio.htm	Edgar Link	pending
ea020571801ex32-2_abvcbio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
abvc-20240331_def.xml	Edgar Link	unprocessable
abvc-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0205718-10q_abvcbio_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abvc-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2024 Q2 Form 10-Q Financial Statement

#000121390024044731 Filed on May 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2024 Q2 Form 10-Q Financial Statement

#000121390024044731 Filed on May 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc